10 completed. 5 Phase 2, 4 Phase 1, 1 Not applicable, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 5 | Completed 5 |
| Phase 1 | 4 | Completed 4 |
| Not applicable | 1 | Completed 1 |
| Phase 3 | 1 | Completed 1 |
Follow IPI-926: new trials by email Literature Review of IPI-926 trials Research Report on IPI-926
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Efficacy and Safety of Patidegib Gel 2% for Preventing Basal Cell Carcinomas on the Face of Adults With Gorlin Syndrome Patidegib Topical Gel, Patidegib Topical Gel with no active patidegib - Gorlin Syndrome | Phase 3 | Completed | Sol-Gel Technologies, Ltd. | 113 | 2024-03-17 | 2026-09-18 |
| Clinical Trial of Patidegib Gel 2%, 4%, and Vehicle Applied Once or Twice Daily to Decrease the GLI1 Biomarker in Sporadic Nodular Basal Cell Carcinomas Patidegib, Vehicle gel - Basal Cell Carcinomas | Phase 2 | Completed | PellePharm, Inc. | 36 | 2016-11-11 | 2019-01-08 |
| Trial of Patidegib Gel 2%, 4%, and Vehicle to Decrease the Number of Surgically Eligible Basal Cell Carcinomas in Gorlin Syndrome Patients Patidegib, Vehicle gel - Basal Cell Nevus Syndrome | Phase 2 | Completed | PellePharm, Inc. | 17 | 2016-06-06 | 2020-07-23 |
| IPI-926 Extension Protocol for Continuation of Treatment With IPI-926 IPI-926 - Basal Cell Carcinoma, Chondrosarcoma | Not applicable | Completed | Infinity Pharmaceuticals, Inc. | 9 | 2012-03-01 | 2012-11-14 |
| A Phase 2 Study With IPI-926 in Patients With Myelofibrosis IPI-926 - Primary Myelofibrosis, Fibrosis, Bone Marrow | Phase 2 | Completed | Infinity Pharmaceuticals, Inc. | 14 | 2011-10-01 | 2012-11-15 |
| FOLFIRINOX Plus IPI-926 for Advanced Pancreatic Adenocarcinoma FOLFIRINOX, IPI-926 - Pancreatic Cancer, Adenocarcinoma | Phase 1 | Completed | Andrew Ko | 15 | 2011-08-23 | 2017-08-08 |
| Pilot Study of Cetuximab and the Hedgehog Inhibitor IPI-926 in Recurrent Head and Neck Cancer IPI-926 and Cetuximab - Recurrent Head and Neck Cancer | Phase 1 | Completed | University of Colorado, Denver | 9 | 2011-04-01 | 2014-01-31 |
| A Safety and Efficacy Study of Patients With Metastatic or Locally Advanced (Unresectable) Chondrosarcoma IPI-926, Placebo Arm - Conventional Chondrosarcoma | Phase 2 | Completed | Infinity Pharmaceuticals, Inc. | 105 | 2011-02-01 | 2013-12-05 |
| A Study Evaluating IPI-926 in Combination With Gemcitabine in Patients With Metastatic Pancreatic Cancer IPI-926 plus gemcitabine, Placebo plus gemcitabine - Metastatic Pancreatic Cancer | Phase 1 / Phase 2 | Completed | Infinity Pharmaceuticals, Inc. | 122 | 2010-04-01 | 2017-03-06 |
| A Phase 1 Study of IPI-926 in Patients With Advanced and/or Metastatic Solid Tumor Malignancies IPI-926 - Neoplasms | Phase 1 | Completed | Infinity Pharmaceuticals, Inc. | 94 | 2008-09-01 | 2012-06-21 |
Basal Cell Nevus Syndrome (3) · Carcinoma, Basal Cell (3) · Neoplasms (2) · Pancreatic Neoplasms (2) · Adenocarcinoma (1) · Bone Neoplasms (1) · Chondrosarcoma (1) · Head and Neck Neoplasms (1) · Primary Myelofibrosis (1)
Infinity Pharmaceuticals, Inc. (5) · PellePharm, Inc. (2) · Andrew Ko (1) · Sol-Gel Technologies, Ltd. (1) · University of Colorado, Denver (1)
United States (9) · Canada (3) · United Kingdom (3) · France (2) · Germany (2) · Italy (2) · Netherlands (2) · Australia (1) · Austria (1) · Norway (1) · Poland (1) · Russia (1) · Spain (1) · Sweden (1)
Robert Ross, MD (2) · Andrew Ko, M.D. (1) · Antonio Jimeno, MD, PhD (1) · Ervin Epstein, MD (1) · John Lear, MD (1) · Pedro Santabarbara, MD (1) · Srdan Verstovsek, M.D.; Ph.D (1) · Tess Schmalbach, MD (1)
2015 (1), 2023 (1)